title: Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).
abstract: OBJECTIVE
  • To determine whether the effect of neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) on the survival of patients with locally advanced urothelial carcinoma (UC) of the bladder treated with radical cystectomy varies with the presence of non-urothelial components in the tumour.
  
  
  METHODS
  • This is a secondary analysis of the Southwest Oncology Group-directed intergroup randomized trial S8710 of neoadjuvant MVAC followed by cystectomy versus cystectomy alone for treatment of locally advanced UC of the bladder. • For the purpose of these analyses, tumours were classified based on the presence of non-urothelial components as either pure UC (n= 236) or mixed tumours (n= 59). Non-urothelial components included squamous and glandular differentiation. • Cox regression models were used to estimate the effect of neoadjuvant MVAC on all-cause mortality for patients with pure UC and for patients with mixed tumours, with adjustment for age and clinical stage.
  
  
  RESULTS
  • There was evidence of a survival benefit from chemotherapy in patients with mixed tumours (hazard ratio 0.46; 95% CI 0.25-0.87; P= 0.02). Patients with pure UC had improved survival on the chemotherapy arm but the survival benefit was not statistically significant (hazard ratio 0.90; 95% CI 0.67-1.21; P= 0.48). • There was marginal evidence that the survival benefit of chemotherapy in patients with mixed tumours was greater than it was for patients with pure UC (interaction P= 0.09).
  
  
  CONCLUSIONS
  • Presence of squamous or glandular differentiation in locally advanced UC of the bladder does not confer resistance to MVAC and in fact may be an indication for the use of neoadjuvant chemotherapy before radical cystectomy.
authors.affiliation: University of Rochester, Rochester, NY, USA.
authors.forename: Emil
authors.initials: E
authors.lastname: Scosyrev
authors.forename: Benjamin W
authors.initials: BW
authors.lastname: Ely
authors.forename: Edward M
authors.initials: EM
authors.lastname: Messing
authors.forename: V O
authors.initials: VO
authors.lastname: Speights
authors.forename: H Barton
authors.initials: HB
authors.lastname: Grossman
authors.forename: David P
authors.initials: DP
authors.lastname: Wood
authors.forename: Ralph W
authors.initials: RW
authors.lastname: de Vere White
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
authors.forename: Donald L
authors.initials: DL
authors.lastname: Trump
authors.forename: Ronald B
authors.initials: RB
authors.lastname: Natale
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Tangen
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015653:Cystectomy; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D008727:Methotrexate